, Columnist
A Leading HIV Drug Is Way Overpriced in the U.S.
A House hearing over the price of Truvada shows a particularly glaring example of a rampant industry practice.
Gilead offers a weak defense of its pricing practices.
Photographer: JB REED/Bloomberg
This article is for subscribers only.
Gilead Sciences Inc. CEO Daniel O'Day has only been on the job since March, and he's already found himself having to defend his company in front of the House Oversight and Reform committee.
O’Day faced questioning at a Thursday hearing over the high price of Truvada, a medicine approved to treat HIV and prevent infection. Activists claim that the price prevents at-risk people from accessing the drug and has helped keep infection rates high.